---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-011830"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:46:29.419259+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q4 revenue $153.6M (+13.5%); FY2025 guidance implies 6-8% organic growth

## Summary
- Q4 net loss from cont ops $0.3M vs ($7.7M) prior year; adj EBITDA $28.3M (+28.3%).
- FY2024 revenue $573.3M (+11.9%); net loss $43.8M vs ($121.2M); adj EBITDA $108.9M (+22.5%).
- FY2025 guidance: net sales $560-570M, adj EBITDA $112-116M, non-GAAP EPS $0.64-$0.68.
- Debt reduced by $48.3M in Q4; Advanced Rehabilitation Business divested for $24.7M proceeds.
- Pain Treatments and Surgical Solutions each delivered double-digit revenue growth for fifth straight quarter.

## SEC filing metadata
- accession: 0001628280-25-011830
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828025011830/0001628280-25-011830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828025011830/bvs-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-011830
- JSON: https://secwatch.observer/filing/0001628280-25-011830.json
- Plain text: https://secwatch.observer/filing/0001628280-25-011830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.